Studies with herpes zoster vaccines in immune compromised patients
Authors:
- 30 October 2017
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 16 (12) , 1217-1230
Abstract
The active component of the herpes zoster vaccine (ZVL), licensed for people ≥50 years of age, is a live attenuated varicella-zoster virus. ZVL is contraindicated for immune compromised individuals, with limited regard to the degree of immunosuppression. Areas covered: This review evaluates phase I and II and observational studies for ZVL, and published reports of the off-label use of ZVL, for conditions and therapies for which investigators considered the risk-benefit for using ZVL to be favorable. It also discusses exploratory trials of ZVL for additional immune compromising conditions, and summarizes clinical guidelines from many countries and professional societies that are based upon recent investigations. Studies in immune compromised patients of investigational vaccines that do not contain live virus are reviewed. Expert commentary: It is likely that past and ongoing research with ZVL will define immune compromising diseases and/or therapies for which the risk-benefit for using ZVL vaccine is favorable. The main variables to consider in this assessment in immune compromised patients are safety, immunogenicity, protection against herpes zoster, and persistence of protection. Vaccination against herpes zoster prior to suppressing immunity is an important clinical strategy, although efficacy of this approach has not been evaluated in a clinical trial.Keywords
This publication has 94 references indexed in Scilit:
- Herpes Zoster Vaccine Effectiveness against Incident Herpes Zoster and Post-herpetic Neuralgia in an Older US Population: A Cohort StudyPLOS Medicine, 2013
- Immune Correlates of Herpes Zoster in HIV-Infected Children and YouthJournal of Virology, 2012
- Safety and Immunogenicity of the Live Attenuated Varicella Vaccine Following T Replete or T Cell-Depleted Related and Unrelated Allogeneic Hematopoietic Cell Transplantation (alloHCT)Transplantation and Cellular Therapy, 2011
- Vaccine Adjuvants: Putting Innate Immunity to WorkImmunity, 2010
- Effectiveness of Varicella Vaccine in Children Infected with HIVThe Journal of Infectious Diseases, 2010
- Influence of Age and Nature of Primary Infection on Varicella‐Zoster Virus–Specific Cell‐Mediated Immune ResponsesThe Journal of Infectious Diseases, 2010
- A PHASE I–II STUDY OF LIVE ATTENUATED VARICELLA-ZOSTER VIRUS VACCINE TO BOOST IMMUNITY IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED CHILDREN WITH PREVIOUS VARICELLAThe Pediatric Infectious Disease Journal, 2009
- Short-Term and Long-Term Effects of Highly Active Antiretroviral Therapy on the Incidence of Herpes Zoster in HIV-Infected ChildrenJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- Strategies for Herpes Zoster Vaccination of Immunocompromised PatientsThe Journal of Infectious Diseases, 2008
- Live, Attenuated Varicella Zoster Vaccination of an Immunocompromised PatientJournal of General Internal Medicine, 2008